Zaltenibart clinical trials
Also written OMS906.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2022
How each study uses zaltenibart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test zaltenibart.
- Dec 2026Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal HemoglobinuriaPhase 2 · Omeros Corporation
Studies
Open first, then newest update. How each study uses zaltenibart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Safety and Efficacy Study of OMS906 in Patients With C3G and ICGNTerminatedPhase 2Omeros CorporationNCT06209736Written as OMS906 study drug
- Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal HemoglobinuriaActive, not recruitingPhase 2Omeros CorporationNCT06298955Written as OMS906 study drug
- Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal HemoglobinuriaCompletedPhase 1Omeros CorporationNCT05889299Written as OMS906
- Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to RavulizumabCompletedPhase 2Omeros CorporationNCT05972967Written as OMS906
What changed recently
From the registry's own updates since Oct 15, 2026.
Stopped1
- Safety and Efficacy Study of OMS906 in Patients With C3G and ICGNTerminatedNov 2, 2026NCT06209736
Codes
What other systems call zaltenibart · ClinicalTrials.gg INT014230
- UNII (FDA) 0SOY20O318ZALTENIBARTOne source FDA
- NCI Thesaurus C207015ZaltenibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 0SOY20O318 | ZALTENIBART | One source FDA |
| NCI Thesaurus | C207015 | Zaltenibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.